Uncommon Cancers of the Bladder

Urachal Adenocarcinoma: A Clinician's Guide for Treatment

“…11 This potential involvement of the umbilicus, which may occur in up to 7% of cases in small series of autopsies, 1 has important implications in developing a surgical strategy that will control the cancer. …”

“…The presence of a midline mass in the bladder that is solid or cystic, especially with small calcifications, is considered a pathognomonic finding. 11 Radiographic imaging is also helpful in determining the extent of disease and whether the tumor is metastatic or potentially surgically resectable. Peritoneal carcinomatosis is a frequent finding in patients with metastatic disease, 2 with additional reports of pseudomyxoma peritonei.…”

“…However, metastases to the bladder rarely affect the bladder dome. 11 Direct extension from nearby organs is usually obvious from clinical symptoms or radiographic imaging. Drop metastases from other nearby organs, including the ovaries or gastrointestinal primary sites, may invade the bladder in the cul-de-sac.…”

“…Early results from this trial in the first group of patients suggest an objective response rate, excluding disease stability, in up to 30%-40% of patients. 11 This trial recently completed accrual, and patients are now in long-term follow-up. While additional time is necessary to obtain long-term survival figures, previous data from our institution suggests a median survival in patients with metastatic disease on the order of 24 months 2 compared to a median of 12 months at other institutions.…”

Urachal carcinoma with liver, lung, and brain metastases: benefit of a new combination chemotherapy (bevacizumab, 5-fluorouracil, irinotecan) – case report

“…There was one additional responder using a combination of paclitaxel, methotrexate, and cisplatin (TMP), and no response in five patients treated with methotrexate, vinblastine, adriamycin, and cisplatin (M-VAC). 16,17 Other reports suggest a single case of long-term survival with gemcitabin and cisplatin (GC), 5 S-1,cisplatin, 18 and cisplatin with irinotecan. 19 The most aggressive cisplatin based combination came from the Memorial Sloan-Kettering Cancer Center (NY, USA).…”